We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $977M
1-Year Est. Return 110.37%
This Fund
S&P 500
This Quarter Est. Return
+25%
1 Year Est. Return
+110.37%
3 Year Est. Return
+306.38%
5 Year Est. Return
+741.86%
10 Year Est. Return
–
AUM
$977M
AUM Growth
+$7.19M
Cap. Flow
-$105M
Cap. Flow %
-10.73%
Top 10 Hldgs %
33.49%
Holding
108
New
18
Increased
27
Reduced
30
Closed
31

Top Buys

Rank Stock Value
1
INBX icon
Inhibrx
INBX
+$25.7M
2
UNH icon
UnitedHealth
UNH
+$20.7M
3
INDV icon
Indivior Pharmaceuticals
INDV
+$13.2M
4
VRDN icon
Viridian Therapeutics
VRDN
+$13.2M
5
DRUG
Bright Minds Biosciences
DRUG
+$13M

Top Sells

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$36.9M
2
SYK icon
Stryker
SYK
+$27.4M
3
QGEN icon
Qiagen
QGEN
+$20M
4
ABBV icon
AbbVie
ABBV
+$16.3M
5
BSX icon
Boston Scientific
BSX
+$14.6M

Sector Composition

Rank Sector Weight
1 Healthcare 98.86%
2 Industrials 0.82%
3 Miscellaneous 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INDV icon
26
Indivior Pharmaceuticals
INDV
$4.1B
$14.9M 1.53%
+364,269
New +$13.2M
NVST icon
27
Envista
NVST
$4.24B
$14.6M 1.49%
553,916
-157,777
-22% -$3.98M
DRUG
28
Bright Minds Biosciences
DRUG
$638M
$14.4M 1.47%
205,053
+164,955
+411% +$13M
XERS icon
29
Xeris Biopharma Holdings
XERS
$1.41B
$14.3M 1.47%
1,807,621
+86,357
+5% +$551K
AVTX icon
30
Avalo Therapeutics
AVTX
$977M
$14.2M 1.45%
+766,290
New +$12.1M
FDMT icon
31
4D Molecular Therapeutics
FDMT
$783M
$12.6M 1.29%
948,184
+425,607
+81% +$4.15M
IMNM icon
32
Immunome
IMNM
$2.97B
$12.6M 1.29%
594,202
+190,715
+47% +$4.08M
STOK icon
33
Stoke Therapeutics
STOK
$1.93B
$11.6M 1.19%
355,443
+18,924
+6% +$607K
WAT icon
34
Waters Corp
WAT
$39.8B
$11.3M 1.16%
30,206
+3,759
+14% +$1.28M
ANRO icon
35
Alto Neuroscience
ANRO
$1.34B
$11.3M 1.16%
+429,035
New +$9.92M
ORKA
36
Oruka Therapeutics
ORKA
$6.06B
$10.8M 1.1%
+113,188
New +$7.54M
ADPT icon
37
Adaptive Biotechnologies
ADPT
$3.9B
$10.4M 1.07%
486,984
-64,831
-12% -$993K
ABSI icon
38
Absci
ABSI
$1.48B
$10.4M 1.06%
894,374
-970,432
-52% -$5.47M
MLYS icon
39
Mineralys Therapeutics
MLYS
$2.7B
$10.3M 1.05%
380,354
+217
+0.1% +$5.95K
COGT icon
40
Cogent Biosciences
COGT
$5.93B
$9.81M 1%
253,365
+153,239
+153% +$5.36M
QURE icon
41
uniQure
QURE
$3.19B
$9.59M 0.98%
208,170
+1,328
+0.6% +$34.8K
TARS icon
42
Tarsus Pharmaceuticals
TARS
$3.63B
$9.44M 0.97%
+150,000
New +$9.58M
AMRX icon
43
Amneal Pharmaceuticals
AMRX
$6.01B
$9.37M 0.96%
541,190
+240,438
+80% +$3.29M
IRTC icon
44
iRhythm Holdings
IRTC
$3.94B
$8M 0.82%
67,267
+27,142
+68% +$3.16M
CYRX icon
45
CryoPort
CYRX
$767M
$7.98M 0.82%
+508,324
New +$6.52M
BSX icon
46
Boston Scientific
BSX
$65.2B
$7.7M 0.79%
180,481
-268,287
-60% -$14.6M
CLYM
47
Climb Bio
CLYM
$864M
$7.35M 0.75%
+563,484
New +$5.82M
AMLX icon
48
Amylyx Pharmaceuticals
AMLX
$3.61B
$7.16M 0.73%
398,782
-222,676
-36% -$3.44M
UPB
49
Upstream Bio Inc
UPB
$326M
$6.47M 0.66%
935,247
+148,464
+19% +$1.24M
RMD icon
50
ResMed
RMD
$31.7B
$6.43M 0.66%
+32,983
New +$6.84M
1
2
3 4 5

Similar funds

KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
ACM
Arini Captial Management London, United Kingdom $975M AUM
FM
Family Management New York $975M AUM 23.16% 1-Year Est. Return
PAMI
Perseverance Asset Management International George Town, Cayman Islands $979M AUM 50.58% 1-Year Est. Return
PFGIA
Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return
SI
Seeds Investor New York $973M AUM 33.7% 1-Year Est. Return
HIGP
Hill Investment Group Partners St. Louis, Missouri $980M AUM 22.33% 1-Year Est. Return
SCA
Stillwater Capital Advisors Devon, Pennsylvania $981M AUM 31.05% 1-Year Est. Return

Parkman Healthcare Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Parkman Healthcare Partners held 108 positions worth $977M, up 0.74% from $970M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Parkman Healthcare Partners withdrew a net $105M in Q2 2026, closing 31 positions and reducing 30 holdings. Its most notable exit was KalVista Pharmaceuticals, an estimated $36.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Industrials and Miscellaneous.

Against the trend, Parkman Healthcare Partners opened a new position in Inhibrx worth $24.3M.

  • Parkman Healthcare Partners's largest Q2 2026 buy was Inhibrx: 256,950 shares worth $24.3M.
  • Parkman Healthcare Partners added most to Viridian Therapeutics in Q2 2026, an estimated $13.2M increase.
  • Parkman Healthcare Partners's biggest Q2 2026 reduction was Stryker, cutting an estimated $27.4M.
  • Parkman Healthcare Partners fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $36.9M.
  • Parkman Healthcare Partners's ten largest holdings make up 33% of its $977M portfolio in Q2 2026.
  • Parkman Healthcare Partners opened 18 new positions and closed 31 in Q2 2026.
  • Parkman Healthcare Partners's portfolio value rose 0.74% quarter-over-quarter to $977M.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.